fluticasone furoate profile

fluticasone furoate: a glucocorticoid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fluticasone furoate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a 2-furoyl substituent at position 17. Used in combination with vilanterol trifenate for treatment of bronchospasm associated with chronic obstructive pulmonary disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	9854489
CHEMBL ID	1676
CHEBI ID	74899
SCHEMBL ID	140504
MeSH ID	M0514058

Synonym
(6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoan drosta-1,4-dien-17-yl furan-2-carboxylate
gw6 ,
veramyst
avamys
fluticasone furoate
allermist
gw-685698x
gw-685698
397864-44-7
veramyst (tn)
fluticasone furoate (jan/usan/inn)
D06315
(6alpha,11beta,16alpha,17alpha)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate
6alpha,9-difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate
gw 685698x
androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-
gw685698x
gsk 685 698
gsk685968
gsk-685968
CHEMBL1676
furamist
ennhale
chebi:74899 ,
arnuity ellipta
flonase sensimist allergy relief
fluticasone furoate [usan:inn]
androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-
unii-js86977wnv
flonase sensimist
js86977wnv ,
alisade
gsk 685698
bdbm50354851
fluticasonum furoas
furoato de fluticasona
furoate de fluticasone
6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate
fluticasone furoate component of arnuity ellipta
fluticasone furoate [usan]
(6.alpha.,11.beta.,16.alpha.,17.alpha.)-6,9-difluoro-17-(((fluoro-methyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
breo ellipta component fluticasone furoate
(6.alpha.,11.beta.,16.alpha.,17.alpha.)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furoate
fluticasone furoate component of trelegy ellipta
trelegy ellipta component fluticasone furoate
fluticasone furoate [vandf]
fluticasone furoate [jan]
fluticasone furoate [who-dd]
fluticasone furoate [ema epar]
6alpha,9-difluoro-17-[[(fluoromethyl)sulfanyl]carbonyl]-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate
(6.alpha.,11.beta.,16.alpha.,17.alpha.)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate
fluticasone furoate [mi]
fluticasone furoate component of breo ellipta
arnuity ellipta component fluticasone furoate
fluticasone furoate [inn]
androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)-
fluticasone furoate [mart.]
fluticasone furoate [orange book]
S6487
DB08906
SCHEMBL140504
[(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
gw685698
(6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoan
drosta-1,4-dien-17-yl furan-2-carboxylate
(6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl furan-2-carboxylate
avamys pound>> veramyst pound>> allermist
BCP18136
HY-15234
Q2166700
gtpl10892
CS-0003822
(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
MS-29934
DTXSID401024827
EN300-19659651
(1r,2r,3as,3bs,5s,9as,9br,10s,11as)-5,9b-difluoro-1-{[(fluoromethyl)sulfanyl]carbonyl}-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl furan-2-carboxylate
E86983
AKOS040744839
(6alpha,11beta,16alpha,17alpha)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furoate
fluticasone furoate (mart.)
6alpha,9-difluoro-17beta-((fluoromethylsulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate
(6alpha,11beta,16alpha,17alpha)-6,9-difluoro-17-(((fluoro-methyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
6alpha,9-difluoro-17beta-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate
androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-
flonase sensimistallergy relief

Excerpt	Reference	Relevance
"Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24-h activity. "	( Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Allen, A; Cole, J; Gul, N; Hicks, W; Jacques, L; Schenkenberger, I; Trivedi, R, 2013)	2.27
"Fluticasone furoate (FF) is an intranasal corticosteroid indicated for the treatment of allergic rhinitis (AR). "	( Fluticasone furoate inhibits cytokine secretion from nasal epithelial cells and reduces eosinophil survival in an in vitro model of eosinophilic inflammation. Alobid, I; de Borja Callejas, F; Fuentes, M; Mullol, J; Pérez-Gonzalez, M; Picado, C; Pujols, L; Roca-Ferrer, J; Valero, A, 2014)	3.29
"Fluticasone furoate (FF) is a new inhaled corticosteroid (ICS) suitable for once-daily dosing in asthma."	( Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. Bateman, ED; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Stone, S; Woodcock, A, 2014)	1.43
"Fluticasone furoate (FF) is a novel, once-daily ICS asthma therapy."	( Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Bateman, ED; Busse, WW; Forth, R; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2014)	1.51
"Fluticasone furoate (FF) is a novel, once-daily inhaled corticosteroid (ICS) that has been shown to improve lung function vs. "	( Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Bateman, ED; Bleecker, ER; Busse, WW; Forth, R; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2014)	2.12
"Fluticasone furoate is an enhanced-affinity glucocorticoid receptor agonist, with potent anti-inflammatory activity."	( Fluticasone furoate/vilanterol: a review of its use in patients with asthma. Syed, YY, 2015)	2.58
"Fluticasone furoate (FF) is a novel inhaled corticosteroid (ICS). "	( Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma. Chang, V; Gray, EL; Thomas, PS, 2016)	2.23
"Fluticasone furoate is a once-daily inhaled corticosteroid. "	( Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Busse, WW; Goldfrad, C; Jacques, L; Kwon, N; O'Byrne, PM; Perrio, M; Yates, LJ, 2016)	2.13
"Fluticasone furoate is a novel enhanced-affinity glucocorticoid for the treatment of allergic rhinitis."	( Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Berger, W; Cheema, A; Nathan, RA; Philpot, E; Silvey, M; Wu, W; Yang, W, 2008)	1.39
"Fluticasone furoate is a novel glucocorticoid developed for the treatment of allergic rhinitis and other inflammatory diseases. "	( Fluticasone furoate nasal spray in allergic rhinitis. Goyal, N; Hochhaus, G, 2008)	3.23
"Fluticasone furoate is an enhanced-affinity glucocorticoid with potent anti-inflammatory activity."	( Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Keith, PK; Scadding, GK, 2008)	2.51
"Fluticasone furoate is a novel enhanced-affinity corticosteroid that has demonstrated favourable safety and tolerability in paediatric patients. "	( Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Máspero, JF; Meltzer, EO; Philpot, E; Tripathy, I; Wu, W, 2009)	2.09
"Fluticasone furoate (FF) is a novel enhanced-affinity corticosteroid for the treatment of allergic rhinitis, delivered by a unique side-actuated device. "	( Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Ellsworth, A; Hampel, F; Jacobs, R; Martin, B; Philpot, E; Toler, W, 2009)	2.14
"Fluticasone furoate is a novel glucocorticoid receptor agonist marketed as a treatment for seasonal and perennial allergic rhinitis. "	( Structure elucidation and spectroscopic analysis of photodegradants of the anti-rhinitis drug fluticasone furoate. Bardsley, B; Gibbon, BH; Smith, MS, 2010)	2.02
"Fluticasone furoate is a promising molecule in the treatment of allergic rhinitis as it fits fully all the official guidelines' criteria. "	( A review of the use of fluticasone furoate since its launch. Canonica, GW; Magnoni, MS; Micheli, D; Villa, E, 2011)	2.12
"Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. "	( Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Forth, R; Haumann, B; Jacques, L; Lötvall, J; Woodcock, A, 2012)	3.26
"Fluticasone furoate (FF) is a novel long-acting inhaled corticosteroid (ICS). "	( Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Bateman, ED; Bleecker, ER; Busse, WW; Forth, R; Haumann, B; Jacques, L; Lötvall, J; Snowise, NG; Woodcock, A, 2011)	2.07
"Fluticasone furoate is a new potent topical glucocorticoid for the treatment of allergic rhinitis."	( An open label, active controlled, multicentric clinical trial to assess the efficacy and safety of fluticasone furoate nasal spray in adult Indian patients suffering from allergic rhinitis. Khippal, N; Kubavat, AH; Mittal, R; Ojha, T; Patel, T; Pawar, P; Shah, UB; Sinha, V, 2011)	1.31
"Fluticasone furoate is a novel enhanced-affinity glucocorticoid for the treatment of AR approved by the Food and Drug Administration in 2007 and recently introduced in India."	( Fluticasone furoate: a new intranasal corticosteroid. Kumar, D; Kumar, R; Parakh, A, )	2.3
"Fluticasone furoate (FF) is an inhaled corticosteroid that is structurally and functionally distinct from fluticasone propionate and is under development as a once-daily therapy for asthma."	( Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Allen, A; Medley, H; Orozco, S, 2012)	2.11
"Fluticasone furoate (FF) is an inhaled corticosteroid (ICS) with 24-hour activity in development as a once-daily treatment for the long-term management of asthma."	( Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Frith, L; Haumann, B; House, KW; Jacques, L; Lötvall, J; Woodcock, A, 2012)	2.21
"Fluticasone furoate (FF) is a novel enhanced-affinity glucocorticoid that has been developed as topical therapy for allergic rhinitis. "	( Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Biggadike, K; Farrow, SN; Gray, DW; Haase, MV; Matthews, JL; Salter, M; Uings, IJ; West, MR, 2007)	2.02
"Fluticasone furoate nasal spray is a new topical intranasal corticosteroid with enhanced affinity for the glucocorticoid receptor and low systemic exposure, which was recently approved in the US for the treatment of seasonal or perennial allergic rhinitis in adults and in children aged >or=2 years. "	( Fluticasone furoate: intranasal use in allergic rhinitis. McCormack, PL; Scott, LJ, 2007)	3.23
"Fluticasone furoate is a recently approved, enhanced- affinity intranasal corticosteroid with low systemic bioavailability and proven efficacy in treating allergic rhinitis."	( A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Caldwell, MF; Gradman, J; Wolthers, OD, 2007)	1.31

Excerpt	Reference	Relevance
" Safety assessments included clinical adverse event (AE) monitoring, clinical laboratory tests, detailed nasal examinations, monitoring of vital signs, and 12-lead ECGs."	( Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Máspero, JF; Meltzer, EO; Philpot, E; Tripathy, I; Wu, W, 2009)	0.65
" Recent studies, which evaluated topical and systemic adverse events associated with ciclesonide (CIC), fluticasone furoate (FF), mometasone furoate (MF), triamcinolone acetonide, fluticasone propionate, budesonide, and beclomethasone dipropionate were summarized."	( Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Blaiss, MS, )	0.35
" Other end points included change from baseline in forced expiratory volume in 1 second, asthma symptom score, adverse events (AEs), 24-hour urinary cortisol excretion, and FF pharmacokinetics."	( Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Allen, A; Medley, H; Orozco, S, 2012)	0.66
" Safety evaluations included adverse events (AEs), non-fasting glucose, potassium, 24-h urinary cortisol excretion, ophthalmic assessments, heart rate and pulse rate."	( Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Andersen, L; Apoux, L; Bateman, ED; Bleecker, ER; Busse, WW; Crawford, J; Hicks, W; Jacques, L; Lötvall, J; O'Byrne, PM; Woodcock, A, 2013)	0.63
"Overall, there were no safety concerns and no major differences were found in treatment-related adverse events when FF and VI were administered alone or in combination."	( The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Allen, A; Hirama, T; Kempsford, R; Nakahara, N; Nohda, S; Wakamatsu, A; Yamada, M, 2013)	0.62
" There were no ophthalmic-related adverse events of LOCS III PSO or IOP that led to early withdrawal."	( Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study. Chylack, LT; Journeay, GE; LaForce, C; Lee, LA; Miller, SD; Silvey, MJ; Wu, W, 2013)	0.73
" Both treatments were well tolerated, with no clinically relevant effect on urinary cortisol excretion or vital signs and no treatment-related serious adverse events."	( Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Bateman, ED; Bleecker, ER; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2013)	0.7
" Six patients in the FF/VI (2%) and three in the FP/SAL (1%) arm experienced serious adverse events, none of which were considered to be drug related."	( A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Agustí, A; Barnes, N; Bourbeau, J; Crim, C; De Backer, W; de Teresa, L; Locantore, N; Zvarich, MT, 2014)	0.65
" Adverse events (AEs) were assessed."	( Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Bateman, ED; Bleecker, ER; Busse, WW; Forth, R; Jacques, L; Kerwin, EM; Lötvall, J; O'Byrne, PM; Stone, S; Woodcock, A, 2014)	0.71
" Pooled adverse events (FF/VI 27%; FP/SAL 28%) and serious adverse events (FF/VI 2%; FP/SAL 3%) were similar between treatments."	( Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Crim, C; Dransfield, MT; Feldman, G; Korenblat, P; LaForce, CF; Locantore, N; Martinez, FJ; Pistolesi, M; Watkins, ML, 2014)	0.68
" Safety assessments included adverse events, laboratory and vital sign measurements, and change from baseline in 24-hour urinary cortisol at Week 24."	( Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. Bateman, ED; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Stone, S; Woodcock, A, 2014)	0.71
" FF 100 μg reported adverse events (63% vs."	( Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. Bateman, ED; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Stone, S; Woodcock, A, 2014)	0.71
" As a safety measure, adverse events and clinical chemistry and hematology were evaluated."	( Efficacy and safety of fluticasone furoate nasal spray in Japanese children with perennial allergic rhinitis: a multicentre, randomized, double-blind, placebo-controlled trial. Honma, G; Komatsubara, M; Okamasa, A; Okubo, K, 2014)	0.71
" The incidence of adverse events was similar between FFNS 55μg(18%) and placebo (19%)."	( Efficacy and safety of fluticasone furoate nasal spray in Japanese children with perennial allergic rhinitis: a multicentre, randomized, double-blind, placebo-controlled trial. Honma, G; Komatsubara, M; Okamasa, A; Okubo, K, 2014)	0.71
" The incidence of adverse events was lower with FF (31%) than with placebo (38%); few were treatment-related (FF 50 mcg: n = 1, <1%; placebo: n = 4, 3%)."	( Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Bateman, ED; Bleecker, ER; Busse, WW; Forth, R; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2014)	0.68
" As a safety measure, adverse events and clinical laboratory data were evaluated."	( Safety and efficacy of fluticasone furoate nasal spray in Japanese children 2 to <15 years of age with perennial allergic rhinitis: a multicentre, open-label trial. Honma, G; Komatsubara, M; Okamasa, A; Okubo, K, 2015)	0.73
"An adverse event was reported by 67% of patients during the treatment and follow-up period, all of which were mild in intensity."	( Safety and efficacy of fluticasone furoate nasal spray in Japanese children 2 to <15 years of age with perennial allergic rhinitis: a multicentre, open-label trial. Honma, G; Komatsubara, M; Okamasa, A; Okubo, K, 2015)	0.73
" Three adverse events were reported; none were severe or led to withdrawal."	( A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers. Ayer, J; Lee, L; Mallett, S; Pascoe, S; Wolstenholme, A; Yang, S, 2015)	0.64
" The incidence of on-treatment adverse events (AEs) was 48% with FF/VI 200/25 mcg and 37-40% with other treatments."	( Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Crim, C; de Guia, T; Newlands, AH; Wang, C; Wang-Jairaj, J; Zheng, J; Zhong, N, 2015)	0.73
" Adverse events (AEs) were also assessed."	( Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Ali, R; Church, A; Donald, A; Kerwin, E; Siler, TM; Sousa, AR, 2015)	0.68
" Safety endpoints included cardiovascular monitoring, cortisol excretion, COPD exacerbations, and adverse events, including prespecified drug effects."	( Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. Covelli, H; Crim, C; Emmett, A; Pek, B; Schenkenberger, I; Scott-Wilson, C, 2016)	0.74
" All treatments were well tolerated, and adverse event incidence was similar across the treatment groups."	( Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination. Allen, A; Bareille, P; Burns, O; Gupta, A; Hughes, S; Miller, SR; Murdoch, RD, 2016)	0.67
" Secondary end points were the mean change from baseline in percentage rescue-free 24-hour periods, daily morning peak expiratory flow, percentage symptom-free 24-hour periods, Asthma Quality of Life Questionnaire score, adverse events, and severe exacerbations."	( Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist. Chen, P; Crawford, J; Jacques, L; Kim, MK; Lin, J; Stone, S; Tang, H; Wang, H, 2016)	0.69
" On-treatment adverse events were 35% with FF/VI (n = 2 [serious]), 31% with placebo; severe exacerbations were FF/VI (n = 1), placebo (n = 7)."	( Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist. Chen, P; Crawford, J; Jacques, L; Kim, MK; Lin, J; Stone, S; Tang, H; Wang, H, 2016)	0.69
" Adverse events (AEs) were monitored."	( Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial. Adachi, M; Goldfrad, C; Jacques, L; Nishimura, Y, 2016)	0.72
" Safety data from 10 parallel-group, randomised, double-blind Phase II and III studies (including 3345 patients who received at least one dose of fluticasone furoate) were integrated to provide information on adverse events, withdrawals, laboratory assessments, vital signs and hypothalamic-pituitary-adrenal axis function."	( Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Busse, WW; Goldfrad, C; Jacques, L; Kwon, N; O'Byrne, PM; Perrio, M; Yates, LJ, 2016)	0.88
" In the integrated analysis, no dose-response relationship was observed for the overall incidence of adverse events and there were no significant effects of fluticasone furoate on hypothalamic-pituitary-adrenal axis function."	( Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Busse, WW; Goldfrad, C; Jacques, L; Kwon, N; O'Byrne, PM; Perrio, M; Yates, LJ, 2016)	0.88
" Annual rates of moderate/severe exacerbations (primary outcome), selected secondary outcomes, and incidence of pneumonia serious adverse events of special interest (SAESI) were compared between randomisation groups across various patient subgroups/baseline treatment strata."	( Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. Bakerly, ND; Boucot, I; Collier, S; Crawford, J; Harvey, C; Leather, DA; New, JP; Vestbo, J; Woodcock, A, 2019)	0.83
" CV safety assessments included proportion of patients with and exposure-adjusted rates of on-treatment CV adverse events of special interest (CVAESI) and major adverse cardiac events (MACE), as well as time-to-first (TTF) CVAESI, and TTF CVAESI resulting in hospitalization/prolonged hospitalization or death."	( Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Criner, G; Day, NC; Dransfield, M; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Kumar, S; Lange, P; Lipson, DA; Lomas, DA; Martin, N; Martinez, FJ; Singh, D; Wise, R, 2020)	0.85
" Safety endpoints were the incidence of adverse events (AEs), including unexpected AEs/adverse drug reactions (ADRs) and serious AEs/ADRs."	( Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma and/or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Cho, EY; Cho, JE; Hwang, KE; Jang, SH, 2023)	1.18

Excerpt	Reference	Relevance
" Pharmacodynamic and PK data were obtained up to 48 h following the VI dose."	( The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Allen, A; Bal, J; Kempsford, R; Rubin, D; Tombs, L, 2013)	0.61
"In study 1, there was no effect of co-administration of ketoconazole and VI on pharmacodynamic or PK parameters."	( The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Allen, A; Bal, J; Kempsford, R; Rubin, D; Tombs, L, 2013)	0.61
" There was no increase in β-agonist systemic pharmacodynamic effects, while serum cortisol was decreased by 27%."	( The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Allen, A; Bal, J; Kempsford, R; Rubin, D; Tombs, L, 2013)	0.61
"To assess the effects of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate/vilanterol (FF/VI) administered in combination."	( Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Allen, A; Davis, A; Hardes, K; Kempsford, R; Tombs, L, 2012)	0.79
"Severe renal impairment had no apparent clinically relevant effects on the pharmacokinetic or pharmacodynamic properties or tolerability of FF/VI."	( Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Allen, A; Davis, A; Hardes, K; Kempsford, R; Tombs, L, 2012)	0.59
" Individual pharmacokinetic parameters of FF and VI differed when co-administered but the differences from monotherapy were not clinically significant."	( The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Allen, A; Hirama, T; Kempsford, R; Nakahara, N; Nohda, S; Wakamatsu, A; Yamada, M, 2013)	0.62
"To investigate the pharmacodynamic and pharmacokinetic profiles of fluticasone furoate (FF)/vilanterol (VI) - a fixed-dose combination of an inhaled corticosteroid (ICS) and a long-acting β2 -agonist for the treatment of asthma and chronic obstructive pulmonary disease - after single and repeat administration in healthy Chinese subjects."	( Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. Allen, A; Chen, X; Du, X; Hu, P; Jiang, J; Kempsford, R; Liu, L; Wu, K; Zheng, X; Zhuang, L, 2015)	0.92
"The co-primary outcome measures reflected pharmacodynamic responses relating to recognized class effects of the two drug classes: reduced serum cortisol level (ICSs), and increased Fridericia's corrected QT interval (QTcF) and reduced serum potassium level (long-acting β2 -agonists)."	( Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. Allen, A; Chen, X; Du, X; Hu, P; Jiang, J; Kempsford, R; Liu, L; Wu, K; Zheng, X; Zhuang, L, 2015)	0.68
"In healthy Chinese subjects, minimal and non-clinically relevant β-adrenergic pharmacodynamic effects were observed with FF/VI doses ranging from 50/25 to 200/25 μg."	( Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. Allen, A; Chen, X; Du, X; Hu, P; Jiang, J; Kempsford, R; Liu, L; Wu, K; Zheng, X; Zhuang, L, 2015)	0.68
" These are the first studies where pharmacokinetic (PK) profile assessment was possible for this inhaled triple fixed-dose combination product."	( Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. Allen, A; Brealey, N; Gupta, A; Henderson, A; Mehta, R; Renaux, J, 2015)	0.74
"Population pharmacokinetic (PK) methods were used to characterize the PK of fluticasone furoate (FF) and vilanterol (VI) in patients with asthma following once daily inhaled FF/VI and FF and to identify significant covariates that impact the PK."	( Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. Allen, A; Siederer, S; Yang, S, 2016)	0.93
"To investigate the potential for systemic pharmacokinetic (PK) and pharmacodynamic (PD) interactions between inhaled fluticasone furoate (FF) and vilanterol (VI) when delivered simultaneously via the ELLIPTA™ dry powder inhaler (DPI)."	( The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol. Allen, A; Bareille, P; Cheesbrough, A; Hamilton, M; Kempsford, R, 2015)	0.86
"The purpose of this study was to investigate potential systemic pharmacokinetic interactions between intranasal fluticasone furoate (FF) and levocabastine (LEVO) when delivered simultaneously via a metered atomizing spray pump."	( Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination. Allen, A; Bareille, P; Burns, O; Gupta, A; Hughes, S; Miller, SR; Murdoch, RD, 2016)	0.88
"These results suggest that in healthy subjects, for LEVO, there is no pharmacokinetic interaction with FF when delivered as FF/LEVO FDC."	( Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination. Allen, A; Bareille, P; Burns, O; Gupta, A; Hughes, S; Miller, SR; Murdoch, RD, 2016)	0.67
" Pharmacokinetic data were analyzed using noncompartmental methods."	( Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination. Ambery, C; Daley-Yates, P; Riddell, K, 2016)	0.64
"A population pharmacokinetic analysis was conducted from a subset of samples obtained from the Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy trial to characterize the pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol in patients with symptomatic COPD following treatment with fluticason furoate-umeclidinium-vilanterol combined in a single inhaler."	( Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. Barnacle, H; Beerahee, M; Birk, R; Brealey, N; Lipson, DA; Mehta, R; Pefani, E; Zhu, CQ, 2018)	0.93
"Population pharmacokinetic methods were used to characterize the pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a fixed-dose combination via a single closed inhaler."	( Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Birk, R; Farrell, C; Hayes, S; Lipson, DA; Mehta, R; Okour, M, 2020)	1.05

Excerpt	Reference	Relevance
"The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2 agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease."	( Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Andersen, L; Apoux, L; Bateman, ED; Bleecker, ER; Busse, WW; Crawford, J; Hicks, W; Jacques, L; Lötvall, J; O'Byrne, PM; Woodcock, A, 2013)	0.93

Excerpt	Reference	Relevance
" Fluticasone furoate is a recently approved, enhanced- affinity intranasal corticosteroid with low systemic bioavailability and proven efficacy in treating allergic rhinitis."	( A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Caldwell, MF; Gradman, J; Wolthers, OD, 2007)	1.5
" Fluticasone furoate demonstrates high systemic clearance, low oral bioavailability and low absolute bioavailability after intranasal administration (<0."	( Fluticasone furoate nasal spray in allergic rhinitis. Goyal, N; Hochhaus, G, 2008)	2.7
" Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimise systemic exposure and reduce systemically driven adverse events."	( Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma. Ballard, SA; Chunn, S; Dybowski, JA; Fulton, CK; Glossop, PA; Guillabert, E; Hewson, CA; Jones, RM; Lamb, DJ; Millan, DS; Napier, CM; Payne-Cook, TA; Renery, ER; Selby, MD; Tutt, MF; Yeadon, M, 2011)	0.37
" Important attributes of fluticasone furoate include low systemic bioavailability (<0."	( Fluticasone furoate: a new intranasal corticosteroid. Kumar, D; Kumar, R; Parakh, A, )	1.88
" The bioavailability of both inhaled FF and FP represents absorption from the lung as the oral bioavailability from the swallowed portion of the inhaled dose is negligible (<1."	( Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Allen, A; Bareille, PJ; Rousell, VM, 2013)	1.83
" Absolute bioavailability was greater (36%-55%) in all East Asian groups than for Caucasian subjects following inhaled FF 800 μg."	( Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Allen, A; Bal, J; Cheesbrough, A; Hamilton, M; Kempsford, R, 2014)	0.64
" As the majority of data were below the assay sensitivity for FF, any potential differences in the bioavailability of FF when delivered alone or as FF/LEVO FDC could not be established."	( Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination. Allen, A; Bareille, P; Burns, O; Gupta, A; Hughes, S; Miller, SR; Murdoch, RD, 2016)	0.67
"Study 1: For intravenous MF and FP, respectively: absolute bioavailability was 11."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.95
"Single inhaled and intravenous doses of MF and FP (400 μg) resulted in similar bioavailability and reductions in serum cortisol."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.95

Excerpt	Relevance	Reference
" At the end of the crossover dosing and after completion of the attributes questionnaires, preference for individual attributes of FF or FP nasal spray and overall patient preference were evaluated in a third questionnaire that asked "Based on these attributes, which product did you prefer overall?" Additionally, a follow-up phone call was conducted 24 hours after the study to assess any adverse events following study treatment."	( Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Dalal, AA; Leflein, J; Lim, J; Meltzer, EO; Meltzer, S; Philpot, EE; Prillaman, BA; Stahlman, JE, 2008)	0.57
"2% ophthalmic solution, fluticasone furoate nasal spray, a tear substitute, or saline nasal spray), dosed with study medication, and challenged 15 minutes later, after which ocular allergic signs and symptoms were assessed."	( A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Abelson, MB; Gomes, PJ; Kennedy, K; Mahr, T; Rosenwasser, LJ, )	0.68
" There was no dose-response relationship across the FF doses studied."	( Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Forth, R; Haumann, B; Jacques, L; Lötvall, J; Woodcock, A, 2012)	1.82
"A dose-response effect was observed for once-daily FF 25-200 μg including (p < 0."	( Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Forth, R; Haumann, B; Jacques, L; Lötvall, J; Medley, H; Woodcock, A, 2012)	0.68
" Results from Phase II studies have shown clinically and statistically significant improvements over placebo in trough (24-hour postdose) forced expiratory volume in 1 second (FEV(1)) after once-daily dosing with FF or VI (VI concurrently with an inhaled corticosteroid) in asthma and VI in COPD."	( Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Boscia, JA; Crim, C; Pudi, KK; Sanford, L; Siederer, SK; Zvarich, MT, 2012)	0.7
"Patients (aged ≥40 years) who completed a 2-week placebo run-in period were randomized to 1 of 18 three-course sequences of placebo and 2 of 3 dose combinations of FF/VI (50/25 μg, 100/25 μg, and 200/25 μg), dosed once daily in the morning."	( Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Boscia, JA; Crim, C; Pudi, KK; Sanford, L; Siederer, SK; Zvarich, MT, 2012)	0.7
" However, morning trough values might have been affected by higher placebo response after morning dosing (18."	( Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Allen, A; Medley, H; Orozco, S, 2012)	0.66
" There was no evidence of a dose-response relationship between FF doses."	( Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Frith, L; Haumann, B; House, KW; Jacques, L; Lötvall, J; Woodcock, A, 2012)	0.77
" This would suggest that FF is exhibiting absorption rate-limited pharmacokinetics following inhaled FF dosing and that the apparent t(½β) is an estimate of absorption rate."	( Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Allen, A; Bareille, PJ; Rousell, VM, 2013)	1.83
" Peak plasma concentration of FF and VI following repeat dosing was up to two times higher compared with the single dose."	( The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Allen, A; Hirama, T; Kempsford, R; Nakahara, N; Nohda, S; Wakamatsu, A; Yamada, M, 2013)	0.62
"In healthy Japanese subjects, no safety concerns were found following repeat dosing of FF and VI or single dosing of FF, VI and FF/VI."	( The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Allen, A; Hirama, T; Kempsford, R; Nakahara, N; Nohda, S; Wakamatsu, A; Yamada, M, 2013)	0.62
"Repeat once-daily dosing of FF/VI (200/25 μg), which is the highest therapeutic strength used in phase III studies, is not associated with QTc prolongation in healthy subjects."	( A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects. Allen, A; Crim, C; Kelly, K; Kempsford, R; Saggu, P, 2014)	0.67
" Higher FF systemic exposure was seen following inhaled dosing in Chinese, Japanese and Korean subjects compared with Caucasian subjects."	( Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Allen, A; Bal, J; Cheesbrough, A; Hamilton, M; Kempsford, R, 2014)	0.64
"Modestly higher (<50%) FF systemic exposure seen in East Asian subjects following inhaled dosing was not associated with a clinically significant effect on serum cortisol, suggesting that a clinical dose adjustment in East Asian subjects is not required."	( Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Allen, A; Bal, J; Cheesbrough, A; Hamilton, M; Kempsford, R, 2014)	0.64
"To investigate the effect of time of day of dosing (morning or evening) on lung function following administration of fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg."	( The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Bal, J; Kempsford, RD; Oliver, A; Quinn, D; Tombs, L, 2013)	0.9
"FF/VI 100/25 administered morning or evening produced clinically significant increases in weighted mean FEV1: the differences [95% confidence interval (CI)] from placebo were 377 mL [293, 462] and 422 mL [337, 507], respectively; the difference between morning and evening dosing was -44 mL [-125, 36]."	( The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Bal, J; Kempsford, RD; Oliver, A; Quinn, D; Tombs, L, 2013)	0.69
"FF/VI 100/25 produces comparable improvements in lung function whether dosed in the morning or evening in subjects with persistent asthma."	( The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Bal, J; Kempsford, RD; Oliver, A; Quinn, D; Tombs, L, 2013)	0.69
" The once-daily dosing might improve adherence in select patients."	( Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Bollmeier, SG; Prosser, TR, 2014)	0.76
"Once-daily repeated dosing of FF/VI, 100/25 µg, using the ELLIPTA dry powder inhaler was as well tolerated as FF, 100 µg, in this small, selected population of 5- to 11-year-old, mostly white/caucasian children with persistent asthma."	( Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Allen, A; Hamilton, M; Inamdar, A; Kempsford, R; Oliver, A; Tombs, L; VanBuren, S, 2014)	0.75
" Fluticasone furoate (FF) is a new inhaled corticosteroid (ICS) suitable for once-daily dosing in asthma."	( Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. Bateman, ED; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Stone, S; Woodcock, A, 2014)	1.62
" Three hundred and fifty-one patients (aged ≥12 years; uncontrolled by non-ICS therapy) were randomized to treatment (1 : 1 : 1) with once-daily FF 50 mcg dosed in the evening, twice-daily fluticasone propionate (FP) 100 mcg or placebo."	( Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Bateman, ED; Busse, WW; Forth, R; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2014)	0.79
"We evaluated the dose-response of umeclidinium (UMEC; a long-acting muscarinic antagonist) combined with fluticasone furoate (FF; an inhaled corticosteroid [ICS]) in patients with asthma."	( The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Edwards, LD; Kerwin, E; Lee, LA; Pascoe, S; Trivedi, R; Yang, S, 2015)	0.99
"Fluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed dose combination that, by simplifying the dosing schedule, allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment."	( Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Capuano, A; Cazzola, M; Matera, MG, 2015)	3.3
" The present study aimed to further characterise the UMEC dose-response relationship with change from baseline trough forced expiratory volume in one second (FEV1) (day 15)."	( Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. Beerahee, M; Goyal, N; Lee, L; Pascoe, S; Trivedi, R; Yang, S, 2015)	0.68
"Within the Study 1 dose range, no significant dose-response was demonstrated."	( Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. Beerahee, M; Goyal, N; Lee, L; Pascoe, S; Trivedi, R; Yang, S, 2015)	0.68
" FF/VI, by simplifying the dosing schedule, allows, for the first time, a shift from twice-daily to once-daily treatment, with an acceptable safety and tolerability profile that is consistent with the ICS/LABA class."	( Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. Cazzola, M; Matera, MG; Rogliani, P, 2015)	1.86
" The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence."	( The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Albertson, TE; Richards, JR; Zeki, AA, 2016)	0.76
" One of the newer fluticasone furoate studies overcomes these limitations and also provides an assessment of a range of doses, suggesting that the therapeutic window is quite narrow and that conventional dosing has probably been too high, although the absolute risk may be different compared to other drugs."	( Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review. Iannella, H; Luna, C; Waterer, G, 2016)	0.77
" The effect of race on PK of FF or VI does not have impact on dosage adjustments for FF/VI in East Asian patients with asthma."	( Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. Allen, A; Siederer, S; Yang, S, 2016)	0.7
" It is hoped that OD dosage of FF/VI can improve adherence and hence asthma control in these patients, however evidence to support this has yet to become available."	( Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma. Chang, V; Gray, EL; Thomas, PS, 2016)	1.88
" In the integrated analysis, no dose-response relationship was observed for the overall incidence of adverse events and there were no significant effects of fluticasone furoate on hypothalamic-pituitary-adrenal axis function."	( Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Busse, WW; Goldfrad, C; Jacques, L; Kwon, N; O'Byrne, PM; Perrio, M; Yates, LJ, 2016)	0.88
" To encourage patient adherence, two classes of medication are often combined in a single medication device; it seems that once-daily dosing offers greatest convenience to patients and may markedly influence adherence."	( Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Bala, MM; Gross-Sondej, I; Jankowski, M; Nowobilski, R; Sliwka, A; Storman, M, 2018)	0.48
" The inhibition in AHR after one week of daily dosing coincided with a significant decrease in FeNO at 7 days."	( Short-term effect of once-daily fluticasone furoate on methacholine-induced bronchoconstriction in mild asthmatics. Blais, CM; Cockcroft, DW; Davis, BE; Okonkwo, CS, 2019)	0.8
" Low plasma concentrations of 6β-hydroxy mometasone were detected after intravenous dosing (Study 1) and after multiple inhaled dosing (Study 2); mometasone was not detected in any samples."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.95
" Repeat dosing of inhaled MF and FP in the therapeutic range (800 μg/day) resulted in greater systemic exposure for MF, and a 35% reduction in serum cortisol that was 2-fold greater than for FP."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.95
" This article reviews efficacy versus systemic activity profiles for various adherence patterns and dosing regimens of fluticasone furoate (FF)-containing and budesonide (BUD)-containing asthma therapies in clinical trials and real-world studies."	( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023)	1.34
"We performed a structured literature review (1 January 2000-3 March 2022) and mathematical modelling analysis of FF-containing and BUD-containing regular daily dosing in patients with mild-to-severe asthma, as-needed BUD/formoterol (FOR) in mild asthma, and BUD/FOR maintenance and reliever therapy (MART) dosing in moderate-to-severe asthma, to assess efficacy (bronchoprotection) and systemic activity (cortisol suppression) profiles of dosing patterns of ICS use in multiple adherence scenarios."	( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023)	1.13
" Focusing on FF-containing or BUD-containing treatments at comparable adherence rates, regular daily FF or FF/vilanterol (VI) dosing provided more prolonged bronchoprotection and fewer systemic effects than daily BUD, daily BUD/FOR, or BUD/FOR MART dosing, especially in low adherence scenarios."	( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023)	1.13

Role	Description
anti-allergic agent	A drug used to treat allergic reactions.
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
anti-asthmatic drug	A drug used to treat asthma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
11beta-hydroxy steroid	Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
corticosteroid	A natural or synthetic analogue of the hormones secreted by the adrenal gland.
fluorinated steroid	A steroid which is substituted with one or more fluorine atoms in any position.
steroid ester
2-furoate ester	Any carboxylic ester where the carboxylic acid component is 2-furoic acid.
thioester	A compound of general formula RC(=O)SR'. Compare with thionoester, RC(=S)OR'.
3-oxo-Delta(1),Delta(4)-steroid	A 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Estrogen receptor	Homo sapiens (human)	IC50 (µMol)	5.0000	0.0000	0.7237	32.7000	AID1476014
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0000	0.4953	10.0000	AID1476013; AID429130
Glucocorticoid receptor	Homo sapiens (human)	Ki	0.0005	0.0001	0.3863	7.0010	AID1375646
Progesterone receptor	Homo sapiens (human)	IC50 (µMol)	0.0210	0.0000	0.5807	10.0000	AID1476016
Mineralocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.1660	0.0003	0.7484	10.0000	AID1476011
Androgen receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.8800	0.0010	1.9794	14.1600	AID1476012
Estrogen receptor beta	Homo sapiens (human)	IC50 (µMol)	5.0000	0.0001	0.5294	32.7000	AID1476015
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Glucocorticoid receptor	Homo sapiens (human)	EC50 (µMol)	0.0004	0.0004	0.0540	1.0000	AID1375648; AID622345
Mineralocorticoid receptor	Homo sapiens (human)	EC50 (µMol)	3.0000	0.0000	0.0126	0.1000	AID1375650
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
antral ovarian follicle growth	Estrogen receptor	Homo sapiens (human)
epithelial cell development	Estrogen receptor	Homo sapiens (human)
chromatin remodeling	Estrogen receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
signal transduction	Estrogen receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Estrogen receptor	Homo sapiens (human)
androgen metabolic process	Estrogen receptor	Homo sapiens (human)
male gonad development	Estrogen receptor	Homo sapiens (human)
negative regulation of gene expression	Estrogen receptor	Homo sapiens (human)
positive regulation of phospholipase C activity	Estrogen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
response to estradiol	Estrogen receptor	Homo sapiens (human)
regulation of toll-like receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic process	Estrogen receptor	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Estrogen receptor	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
response to estrogen	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
stem cell differentiation	Estrogen receptor	Homo sapiens (human)
regulation of inflammatory response	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
RNA polymerase II preinitiation complex assembly	Estrogen receptor	Homo sapiens (human)
uterus development	Estrogen receptor	Homo sapiens (human)
vagina development	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord elongation	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	Estrogen receptor	Homo sapiens (human)
regulation of branching involved in prostate gland morphogenesis	Estrogen receptor	Homo sapiens (human)
mammary gland branching involved in pregnancy	Estrogen receptor	Homo sapiens (human)
mammary gland alveolus development	Estrogen receptor	Homo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongation	Estrogen receptor	Homo sapiens (human)
protein localization to chromatin	Estrogen receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of miRNA transcription	Estrogen receptor	Homo sapiens (human)
regulation of epithelial cell apoptotic process	Estrogen receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
ovulation from ovarian follicle	Progesterone receptor	Homo sapiens (human)
glandular epithelial cell maturation	Progesterone receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Progesterone receptor	Homo sapiens (human)
signal transduction	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
cell-cell signaling	Progesterone receptor	Homo sapiens (human)
positive regulation of gene expression	Progesterone receptor	Homo sapiens (human)
negative regulation of gene expression	Progesterone receptor	Homo sapiens (human)
paracrine signaling	Progesterone receptor	Homo sapiens (human)
negative regulation of phosphorylation	Progesterone receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
lung alveolus development	Progesterone receptor	Homo sapiens (human)
regulation of epithelial cell proliferation	Progesterone receptor	Homo sapiens (human)
progesterone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
maintenance of protein location in nucleus	Progesterone receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Progesterone receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Mineralocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Mineralocorticoid receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Estrogen receptor beta	Homo sapiens (human)
regulation of DNA-templated transcription	Estrogen receptor beta	Homo sapiens (human)
signal transduction	Estrogen receptor beta	Homo sapiens (human)
cell-cell signaling	Estrogen receptor beta	Homo sapiens (human)
negative regulation of cell growth	Estrogen receptor beta	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Estrogen receptor beta	Homo sapiens (human)
positive regulation of DNA-templated transcription	Estrogen receptor beta	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Estrogen receptor beta	Homo sapiens (human)
cellular response to estradiol stimulus	Estrogen receptor beta	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Estrogen receptor beta	Homo sapiens (human)
cellular response to estrogen stimulus	Estrogen receptor beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
TFIIB-class transcription factor binding	Estrogen receptor	Homo sapiens (human)
transcription coregulator binding	Estrogen receptor	Homo sapiens (human)
transcription corepressor binding	Estrogen receptor	Homo sapiens (human)
transcription coactivator binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
chromatin binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor	Homo sapiens (human)
steroid binding	Estrogen receptor	Homo sapiens (human)
protein binding	Estrogen receptor	Homo sapiens (human)
calmodulin binding	Estrogen receptor	Homo sapiens (human)
beta-catenin binding	Estrogen receptor	Homo sapiens (human)
zinc ion binding	Estrogen receptor	Homo sapiens (human)
TBP-class protein binding	Estrogen receptor	Homo sapiens (human)
enzyme binding	Estrogen receptor	Homo sapiens (human)
protein kinase binding	Estrogen receptor	Homo sapiens (human)
nitric-oxide synthase regulator activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor binding	Estrogen receptor	Homo sapiens (human)
estrogen response element binding	Estrogen receptor	Homo sapiens (human)
identical protein binding	Estrogen receptor	Homo sapiens (human)
ATPase binding	Estrogen receptor	Homo sapiens (human)
14-3-3 protein binding	Estrogen receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Estrogen receptor	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
transcription coactivator binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
DNA binding	Progesterone receptor	Homo sapiens (human)
nuclear steroid receptor activity	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor activity	Progesterone receptor	Homo sapiens (human)
steroid binding	Progesterone receptor	Homo sapiens (human)
protein binding	Progesterone receptor	Homo sapiens (human)
zinc ion binding	Progesterone receptor	Homo sapiens (human)
enzyme binding	Progesterone receptor	Homo sapiens (human)
identical protein binding	Progesterone receptor	Homo sapiens (human)
ATPase binding	Progesterone receptor	Homo sapiens (human)
estrogen response element binding	Progesterone receptor	Homo sapiens (human)
nuclear receptor activity	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Mineralocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Mineralocorticoid receptor	Homo sapiens (human)
nuclear steroid receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
steroid binding	Mineralocorticoid receptor	Homo sapiens (human)
protein binding	Mineralocorticoid receptor	Homo sapiens (human)
zinc ion binding	Mineralocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Mineralocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Mineralocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Mineralocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor beta	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor beta	Homo sapiens (human)
DNA binding	Estrogen receptor beta	Homo sapiens (human)
nuclear steroid receptor activity	Estrogen receptor beta	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor beta	Homo sapiens (human)
steroid binding	Estrogen receptor beta	Homo sapiens (human)
protein binding	Estrogen receptor beta	Homo sapiens (human)
zinc ion binding	Estrogen receptor beta	Homo sapiens (human)
enzyme binding	Estrogen receptor beta	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor beta	Homo sapiens (human)
estrogen response element binding	Estrogen receptor beta	Homo sapiens (human)
receptor antagonist activity	Estrogen receptor beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Estrogen receptor	Homo sapiens (human)
nucleoplasm	Estrogen receptor	Homo sapiens (human)
transcription regulator complex	Estrogen receptor	Homo sapiens (human)
cytoplasm	Estrogen receptor	Homo sapiens (human)
Golgi apparatus	Estrogen receptor	Homo sapiens (human)
cytosol	Estrogen receptor	Homo sapiens (human)
plasma membrane	Estrogen receptor	Homo sapiens (human)
membrane	Estrogen receptor	Homo sapiens (human)
chromatin	Estrogen receptor	Homo sapiens (human)
euchromatin	Estrogen receptor	Homo sapiens (human)
protein-containing complex	Estrogen receptor	Homo sapiens (human)
nucleus	Estrogen receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
plasma membrane	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Progesterone receptor	Homo sapiens (human)
mitochondrial outer membrane	Progesterone receptor	Homo sapiens (human)
cytosol	Progesterone receptor	Homo sapiens (human)
chromatin	Progesterone receptor	Homo sapiens (human)
nucleus	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Mineralocorticoid receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Mineralocorticoid receptor	Homo sapiens (human)
cytosol	Mineralocorticoid receptor	Homo sapiens (human)
chromatin	Mineralocorticoid receptor	Homo sapiens (human)
receptor complex	Mineralocorticoid receptor	Homo sapiens (human)
nucleus	Mineralocorticoid receptor	Homo sapiens (human)
nucleus	Estrogen receptor beta	Homo sapiens (human)
nucleoplasm	Estrogen receptor beta	Homo sapiens (human)
mitochondrion	Estrogen receptor beta	Homo sapiens (human)
intracellular membrane-bounded organelle	Estrogen receptor beta	Homo sapiens (human)
chromatin	Estrogen receptor beta	Homo sapiens (human)
nucleus	Estrogen receptor beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay ID	Title	Year	Journal	Article
AID429130	Agonist activity at GR in human A549 cells by NF-kappaB transrepression assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Highly tractable, sub-nanomolar non-steroidal glucocorticoid receptor agonists.
AID1375648	Induction of nuclear translocation of human recombinant ProLabel-tagged glucocorticoid receptor expressed in CHO-K1 cells after 3 hrs by luminescence method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1476013	Displacement of fluormone labelled GS Red from human recombinant glucocorticoid receptor after 2 hrs by fluorescence polarization assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
AID1375657	MRTlast in Sprague-Dawley rat plasma at 1 umol/kg, it by HPLC-MS/MS method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1068841	n-Octanol-buffer partition coefficient, log D of the compound at pH 7.4 by shake-flask method	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
AID1375652	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release preincubated for 15 mins followed by LPS challenge measured after 18 hrs by Griess assay	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1476016	Displacement of fluormone labelled PL Red from human recombinant progesterone receptor after 1 to 6 hrs ligand by fluorescence polarization assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
AID1375654	Cmax in Sprague-Dawley rat lung at 1 umol/kg, it by HPLC-MS/MS method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1476014	Displacement of fluormone labelled EL Red from human recombinant estrogen receptor alpha after 1 to 5 hrs by fluorescence polarization assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
AID1476015	Displacement of fluormone labelled EL Red from human recombinant estrogen receptor beta after 1 to 5 hrs by fluorescence polarization assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
AID1375653	Cmax in Sprague-Dawley rat plasma at 1 umol/kg, it by HPLC-MS/MS method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID622346	Inhibition of TNFalpha release in human PBMC by ELISA assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma.
AID1375650	Induction of nuclear translocation of human recombinant ProLabel-tagged mineralocorticoid receptor expressed in CHO-K1 cells after 3 hrs by luminescence method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1476012	Displacement of fluormone labelled AL green from rat recombinant His/GST-tagged androgen receptor LBD after 4 to 6 hrs by fluorescence polarization assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
AID1476011	Displacement of [3H]-aldosterone from N terminal maltose binding protein tagged human mineralocorticoid receptor LBD (726 to 984 residues) expressed in baculovirus infected high five cells after 8 hrs by scintillation proximity assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
AID1375651	Selectivity ratio of EC50 for human recombinant ProLabel-tagged mineralocorticoid receptor to EC50 for human recombinant ProLabel-tagged glucocorticoid receptor	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1654621	Volume of distribution in human at 0.25 mg, iv administered as single dose measured up to 168 hrs	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID622347	Inhibition of TNFalpha release in LPS-stimulated human whole blood by ELISA assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma.
AID1654620	Half life in human at 0.25 mg, iv administered as single dose measured up to 168 hrs	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID622345	Agonist activity at GR in human SW1353 cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma.
AID1068810	Inhibition of ovalbumin-induced lung eosinophilia in Dunkin-Hartley guinea pig at 0.3 umol/kg administered intratracheally 2 hrs before ovalbumin challenge	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
AID1375655	AUClast in Sprague-Dawley rat plasma at 1 umol/kg, it by HPLC-MS/MS method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1375656	AUClast in Sprague-Dawley rat lung at 1 umol/kg, it by HPLC-MS/MS method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1375646	Displacement of [3H]dexamethasone from human recombinant glucocorticoid receptor expressed in insect cells after 24 hrs by scintillation proximity assay	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID1375658	MRTlast in Sprague-Dawley rat lung at 1 umol/kg, it by HPLC-MS/MS method	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
AID404878	Displacement of [3H]Dexamethasone from glucocorticoid receptor in human lung tissue relative to Dexamethasone	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain.
AID1654622	Oral bioavailability in human at 2 mg administered as single dose and measured up to 168 hrs	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID1375665	Antiinflammatory activity in LPS-induced Sprague-Dawley rat neutrophilic lung inflammation model assessed as inhibition of neutrophilic infiltration in bronchoalveolar lavage at ID80, it preincubated for 24 hrs followed by LPS challenge measured after 4 h	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (10.78)	29.6817
2010's	169 (72.84)	24.3611
2020's	38 (16.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	134 (53.17%)	5.53%
Reviews	37 (14.68%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	2 (0.79%)	0.25%
Other	79 (31.35%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
bromide Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	7.69	4	4	halide anion; monoatomic bromine
carbamates [no description available]	6.57	3	3	amino-acid anion
histamine [no description available]	5.35	2	2	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	9.02	7	7	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
azelastine azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.	2.13	1	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	4.4	1	1	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.25	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.25	1	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.25	1	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
halothane [no description available]	2.25	1	0	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	5.82	2	2	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
oxymetazoline Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251). oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.	9.37	1	1	carboxamidine; imidazolines; phenols	alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.25	1	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.25	1	0	benzothiazoles
sevoflurane Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.	2.25	1	0	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
fluoroacetic acid fluoroacetic acid: N1 same as NM; RN given refers to parent cpd. fluoroacetic acid : A haloacetic acid that is acetic acid in which one of the methyl hydrogens is substituted by fluorine.	2.25	1	0	haloacetic acid; organofluorine compound	EC 4.2.1.3 (aconitate hydratase) inhibitor
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	4.34	1	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	2.25	1	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	6.77	4	3	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	3.44	1	1	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methacholine chloride Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)	5.37	2	1	quaternary ammonium salt
fluocinolone acetonide Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.	2.06	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
trifluoroethanol Trifluoroethanol: A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.	2.25	1	0	fluoroalcohol
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.05	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
1-chloro-2-nitrobenzene [no description available]	2.25	1	0	C-nitro compound; monochlorobenzenes
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	15	42	21	quinuclidines; saturated organic heterobicyclic parent
phenetole phenetole : An aromatic ether in which the ether oxygen is bonded to an ethyl and a phenyl group.	2.25	1	0	aromatic ether
2-chloropyridine 2-chloropyridine: structure given in first source	2.25	1	0	monochloropyridine
tetrafluoroethylene tetrafluoroethylene: RN given refers to parent cpd; structure	2.25	1	0	fluorocarbon
hexafluoropropene [no description available]	2.25	1	0
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.21	1	0	indazole
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.13	1	0
2-bromopropionic acid, (dl)-isomer 2-bromopropionic acid: RN given refers to cpd without isomeric designation	2.25	1	0
2-chloropropionic acid 2-chloropropionic acid: RN given refers to parent cpd with specified chlorine locant; structure	2.25	1	0
alpha-fluoro-beta-alanine alpha-fluoro-beta-alanine: metabolite of HCFU & 5-fluorouracil; structure in first source	2.25	1	0	organonitrogen compound; organooxygen compound
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.06	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
7-ethoxycoumarin 7-ethoxycoumarin : A member of the class of coumarins that is umbelliferone in which the hydroxy group at position 7 is replaced by an ethoxy group.	2.25	1	0	aromatic ether; coumarins
substance p [no description available]	3.46	1	1	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
levocabastine levocabastine: for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis	6.5	3	3	piperidines
perfluoroisobutylene [no description available]	2.25	1	0
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	2.25	1	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
neplanocin a neplanocin A: neplanocins are antitumor antibiotics & carbocyclic analogs of purine nucleosides from Ampullarilla regularis A11079; see also neplanocin B, neplanocin C, neplanocin D & neplanocin F; structure in first source; a potent inhibitor of S-adenosylhomocysteine hydrolase	2.25	1	0
bendamustine hydrochloride [no description available]	3.59	1	1
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.06	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
fludioxonil fludioxonil: structure in first source. fludioxonil : A member of the class of benzodioxoles that is 2,2-difluoro-1,3-benzodioxole substituted at position 4 by a 3-cyanopyrrol-4-yl group. A fungicide seed treatment for control of a range of diseases including Fusarium, Rhizoctonia and Alternaria.	2.25	1	0	benzodioxoles; nitrile; organofluorine compound; pyrroles	androgen antagonist; antifungal agrochemical; estrogen receptor agonist
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	4.51	1	1	iditol	fungal metabolite
2,6-diamino-9-(2-hydroxyethoxymethyl)purine 2,6-diamino-9-(2-hydroxyethoxymethyl)purine: adenosine deaminase converts above cpd to acylovir	2.25	1	0
mometasone furoate Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.	5.91	8	3	11beta-hydroxy steroid; 2-furoate ester; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; organochlorine compound; steroid ester	anti-allergic agent; anti-inflammatory drug
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.77	3	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
roflumilast [no description available]	2.13	1	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
pa 824 pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source	2.25	1	0
3,3,3-trifluoroalanine 3,3,3-trifluoroalanine: RN refers to (DL)-isomer; inhibits pyridoxal-5'-phosphate dependent cystathionine beta-lyase	2.25	1	0
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	9.61	12	3	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
montelukast montelukast: a leukotriene D4 receptor antagonist	3.99	1	1	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
olopatadine hydrochloride Olopatadine Hydrochloride: An antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of ALLERGIC CONJUNCTIVITIS.	4.39	1	1	dibenzooxazepine
fluticasone Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.	13.29	33	13	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 3-oxo-Delta(4) steroid; corticosteroid; fluorinated steroid; thioester	anti-allergic agent; anti-asthmatic drug
benzyloxycarbonyl-phe-ala-fluormethylketone cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).	2.25	1	0
tiotropium bromide Tiotropium Bromide: A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.. tiotropium bromide : An organic bromide salt having (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane as the counterion. Used (in the form of the hydrate) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.	12.04	4	2
6 beta-hydroxycortisol 6 beta-hydroxycortisol: RN given refers to the (6beta,11beta)-isomer; see also record for 6 alpha-hydrocortisol. 6beta-hydroxycortisol : A C21-steroid that is cortisol bearing an additional hydroxy substituent at the 6beta-position. In humans, it is produced as a metabolite of cortisol by cytochrome p450-3A4 (CYP3A4, an important enzyme involved in the metabolism of a variety of exogenous and endogenous compounds) and can be used to detect moderate and potent CYP3A4 inhibition in vivo.	4.34	1	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; 6beta-hydroxy steroid; C21-steroid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mammalian metabolite; probe
ciclesonide ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis	2.13	1	0	organic molecular entity
indacaterol indacaterol: a beta2 adrenoceptor agonist; indacaterol is the (R)-isomer; structure in first source. indacaterol : A monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary disease.	2.13	1	0	indanes; monohydroxyquinoline; quinolone; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent
10,10-bis((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone DMP 543: neurotransmitter release enhancer; structure given in first source	2.25	1	0	anthracenes
vilanterol [no description available]	20.25	138	88	benzyl alcohols; dichlorobenzene; ether; phenols; secondary amino compound	beta-adrenergic agonist; bronchodilator agent
batefenterol batefenterol: a bronchodilator	6.57	3	3
olodaterol [no description available]	7.6	1	0	aromatic ether; benzoxazine; phenols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent
gsk573719 GSK573719: Muscarinic Antagonist. umeclidinium : A quaternary ammonium ion that is quinuclidine substituted at positions 1 and 4 by 2-(benzyloxy)ethyl and hydroxy(diphenyl)methyl groups respectively.	15.03	43	21
anacetrapib [no description available]	2.25	1	0
(9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Beclomethasone: An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA.. beclomethasone : A 17alpha-hydroxy steroid that is prednisolone in which the hydrogens at the 9alpha and 16beta positions are substituted by a chlorine and a methyl group, respectively.	2.81	3	0	21-hydroxy steroid
lumacaftor lumacaftor: a corrector of CF transmembrane conductance regulator (CTFR); structure in first source. lumacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fibrosis.	2.25	1	0	aromatic amide; benzodioxoles; benzoic acids; cyclopropanes; organofluorine compound; pyridines	CFTR potentiator; orphan drug
piperidines Piperidines: A family of hexahydropyridines.	6.5	3	3
budesonide, formoterol fumarate drug combination Budesonide, Formoterol Fumarate Drug Combination: A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	4.22	2	0
fluticasone propionate, salmeterol xinafoate drug combination Fluticasone-Salmeterol Drug Combination: A drug combination of fluticasone and salmeterol that is used as an inhaler formulation to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	10.44	10	8
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	3.45	1	1
chf6001 tanimilast: a phosphodiesterase-4 inhibitor; structure in first source	2.1	1	0
leptin Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.	7.1	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Asthma, Bronchial [description not available]	0	21.13	303	69
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	1	23.13	303	69
Chronic Illness [description not available]	0	5	4	2
Eosinophilia, Tropical [description not available]	0	2.52	2	0
Obstructive Lung Diseases [description not available]	0	2.1	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	5	4	2
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	0	2.52	2	0
Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.	1	4.1	1	0
Edema, Pulmonary [description not available]	0	2.15	1	0
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	0	2.15	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	14.8	41	37
Pneumonia Infection of the lung often accompanied by inflammation.	0	14.8	41	37
Airflow Obstruction, Chronic [description not available]	0	20.36	154	102
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	1	22.36	154	102
Innate Inflammatory Response [description not available]	0	5.33	4	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	5.33	4	1
Rhinitis, Allergic, Nonseasonal [description not available]	0	12.08	18	9
Rhinitis, Allergic, Perennial Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.	1	14.08	18	9
2019 Novel Coronavirus Disease [description not available]	0	3.99	1	1
Allergic Rhinitis [description not available]	0	9.85	12	5
Rhinitis, Allergic An inflammation of the NASAL MUCOSA triggered by ALLERGENS.	0	9.85	12	5
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.21	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	9.01	9	7
Disease Exacerbation [description not available]	0	13.31	24	18
Apoplexy [description not available]	0	4.96	2	1
Angina at Rest [description not available]	0	4.96	2	1
Anterior Circulation Transient Ischemic Attack [description not available]	0	3.64	1	1
Cardiovascular Stroke [description not available]	0	4.96	2	1
Angina, Unstable Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.	0	4.96	2	1
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	0	3.64	1	1
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	4.96	2	1
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	4.96	2	1
Adverse Drug Event [description not available]	0	3.17	1	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	3.17	1	0
Acute Symptom Flare [description not available]	0	6.62	3	3
Apnea, Obstructive Sleep [description not available]	0	4.48	2	2
Nasal Diseases [description not available]	0	5.38	2	2
Sleep Apnea, Obstructive A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)	0	4.48	2	2
Nasal Catarrh [description not available]	0	6.07	5	2
Sinus Infections [description not available]	0	5.7	3	2
Nasal Polyps Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations.	0	4	2	1
Rhinitis Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.	1	8.07	5	2
Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.	0	10.7	3	2
Hay Fever [description not available]	0	13.95	31	18
Rhinitis, Allergic, Seasonal Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.	1	18.62	62	36
Catarrh Inflammation of a mucous membrane with increased flow of mucous in humans or animals. Catarrh is used mostly in a historical context.	0	3.09	1	0
Haemophilus Infections Infections with bacteria of the genus HAEMOPHILUS.	0	3.09	1	0
Moraxella Infections [description not available]	0	3.09	1	0
Common Cold A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.	0	3.09	1	0
Breathlessness [description not available]	0	7.6	4	4
Dyspnea Difficult or labored breathing.	0	7.6	4	4
Cranial Nerve II Diseases [description not available]	0	2.21	1	0
Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	0	2.21	1	0
Intraocular Pressure The pressure of the fluids in the eye.	0	4.84	2	1
Optic Nerve Diseases Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.	0	2.21	1	0
Cataract, Membranous [description not available]	0	4.39	1	1
Nasal Bleeding [description not available]	0	4.39	1	1
Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)	0	4.39	1	1
Epistaxis Bleeding from the nose.	0	4.39	1	1
Electrocardiogram QT Prolonged [description not available]	0	4.4	1	1
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	0	4.4	1	1
Moniliasis, Oral [description not available]	0	4.4	1	1
Candidiasis, Oral Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed)	0	4.4	1	1
Sneezing The sudden, forceful, involuntary expulsion of air from the NOSE and MOUTH caused by irritation to the MUCOUS MEMBRANES of the upper RESPIRATORY TRACT.	0	3.51	1	1
Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM.	0	2.13	1	0
Airway Obstruction Any hindrance to the passage of air into and out of the lungs.	0	4.45	1	1
Eye Disorders [description not available]	0	5.31	2	2
Eye Diseases Diseases affecting the eye.	0	5.31	2	2
Allergic Conjunctivitis [description not available]	0	5.27	4	1
Conjunctivitis, Allergic Conjunctivitis due to hypersensitivity to various allergens.	0	5.27	4	1
Abnormal Deep Tendon Reflex [description not available]	0	4.35	1	1
Reflex, Abnormal An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.	0	4.35	1	1
Allergic Reaction [description not available]	0	3.83	2	1
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	0	3.83	2	1
Bronchial Hyperreactivity Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.	0	3.44	1	1
Bilateral Headache [description not available]	0	4.37	1	1
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	0	4.37	1	1
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	4.37	1	1
Bronchospasm, Exercise-Induced [description not available]	0	3.46	1	1
Asthma, Exercise-Induced Asthma attacks following a period of exercise. Usually the induced attack is short-lived and regresses spontaneously. The magnitude of postexertional airway obstruction is strongly influenced by the environment in which exercise is performed (i.e. inhalation of cold air during physical exertion markedly augments the severity of the airway obstruction; conversely, warm humid air blunts or abolishes it).	0	3.46	1	1
Acute Disease Disease having a short and relatively severe course.	0	4.37	1	1
Hepatic Insufficiency Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.	0	7.5	4	4
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	0	7.5	4	4
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	0	7.5	4	4
Respiration Disorders Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.	0	2.03	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.03	1	0
Stunted Growth [description not available]	0	3.42	1	1
Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.	0	3.42	1	1

fluticasone furoate

Description

Cross-References

Synonyms (86)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (7)

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (81)

Molecular Functions (37)

Ceullar Components (21)

Bioassays (28)

Research

Studies (232)

Market Indicators

Research Demand Index: 53.98

Study Types

fluticasone furoate

Description

Cross-References

Synonyms (86)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (7)

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (81)

Molecular Functions (37)

Ceullar Components (21)

Bioassays (28)

Research

Studies (232)

Market Indicators

Research Demand Index: 53.98

Study Types

Related Drugs (75)

Related Conditions (88)